In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an infectious disease that has spread worldwide. Current treatments are limited in both availability and efficacy, such that improving our understanding of the factors that facilitate infection is urgently needed to more effectively treat infected individuals and to curb the pandemic. We and others have previously demonstrated the significance of interactions between the SARS-CoV-2 spike protein, integrin α5β1, and human ACE2 to facilitate viral entry into host cells in vitro. We previously found that inhibition of integrin α5β1 by the clinically validated small peptide ATN-161 inhibits these spike protein interactions and cell infection in vitro. In continuation with our previous findings, here we have further evaluated the t

SUBMITTER: Amruta N 

PROVIDER: S-EPMC8352850 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature